{"name":"Ollin Biosciences, Inc.","slug":"ollin-biosciences-inc","ticker":"","exchange":"","domain":"ollin.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxNd3llVVFOYnFydE93bGRidTZmd0NOaGtLamdmSXBRR2pBc1ZCa3Y5ZGVDa3BuQllPX09LRTh5NFB3OWE0ZGhHN3VPY0FfcGxDVzRSeGxVdXVxT2tPV25uQ09FSVNhY0wzLTBiV3QtU2lsU3FGcGhZUjFLSV9aTWJ3Rkw2cVlxUi1ORkhRVW9GRUxkZzJqVjBEeVN1YjFva3d6Ny1xMU4zYlJkNVgyQnprZFNKUjNCNV9IZnpsdzh4N19wcUNxckxaaEpmZm8zeUhIS1JKNDVKcTZLb3pmSVY4c0RRLVgwX3FxZ29DcnB3SU1rQVRmclZvdVNWRWM2UkdpcW1vYWM1QjI3LU5MelNxNjlSQ2czLWhWLUNVWkRPcHdfTEtUdTU2Qm1LdnJyZDZadGpqNzhWVndKRUhPeHB6SC1xb1hqQThXZnRpMF8xeGdKeFp4TDZLMQ?oc=5","date":"2026-03-30","type":"regulatory","source":"Business Wire","summary":"Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema - Business Wire","headline":"Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"regulatory","source":"BioSpace","summary":"Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related M","headline":"Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxONFZZcXo4NHBnTWxYYmZnZmtWWlZERlpIamFaa2VMSnAyTGxIWTVkcVAxd2JjTXZNajRIWkpZd3h1MWktUHN0eDhsOG1MeTZtM0duZlVVYUJqQUJ5RHlfY1lHUlh0NVZENWJ5NUhGUzlCazNMRkJZM0ZmNUhSc184OUVWeWRvVUJraFFkTGNCdFd3VTBTb0JlVG82bFc4RGxLSmVmX2Jma3ozT1hmQWxXNXJTRWpwXzNOTlVaWWRuRGduNlk?oc=5","date":"2026-01-09","type":"trial","source":"Ophthalmology Times","summary":"Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab - Ophthalmology Times","headline":"Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPUGs0ZE8tQTFKTG8zdFRLYm1KVjlGSmtoV2NfNjBManVfOVRnU0llRW5XQWhIaV9NVGFPaGp0MzVzM0NFRGxUU29LQWNLLXd1NWlZQWd1VDVTUWZsc0R0cXpmeWFvdF9Rb1JJajNzZEdITjlMTnBwQXZZc0k3YjU3SVZEXzJyd1Z2LU9DaGctUjBMOHZzLUxkU3hIQUVHSHIxN2FkQ0lyZHNmcXBXSVNtTlphblFnZjJSS2F2OFplYW1nbkcxMktVUE9yUVNua2JuWTAzYmcwQ0xxakdsV0lVRUV6aXdYRkNHRVVOZlN5TE5RQQ?oc=5","date":"2025-12-18","type":"pipeline","source":"Business Wire","summary":"Ollin Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 - Business Wire","headline":"Ollin Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOS296MDR5YXlISTgwdUJkUGRPblphZ25ic0JfQXNMV1BJZXk0anBnTVcwUTVWbkFzWkRBZXRCWGU3MDNlM2NZVURfd1J2N2dDSFY4dkUxT2F1MXdhV3M2QlRmcmcyMzZxTFZVaW14cW1pRzNpX0FRVFI3ZXBiaHMxY09pNS00aTlONFozNms4ek9pa0RIQncyT2FXQko5MGRJSFhpZVNzSUZ1REZ0VHJ4RA?oc=5","date":"2025-09-24","type":"pipeline","source":"Eyes On Eyecare","summary":"Ollin Biosciences debuts with next-gen ophthalmic pipeline - Eyes On Eyecare","headline":"Ollin Biosciences debuts with next-gen ophthalmic pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQOEdtTV9FSTJpbko0VDFFUXhsazZtanVxTDQwenNTLWtnR1JOT2pWZHZPcDA0bFBCMzB4M1I5eVlXbFdpekxDZGFxWHhXa2tSUHhuYmFrUk9wRVBtSkdfYmxjLUtkSFNlUWozeDRncjhDMDl5RWtlV2J4ZDVBdUhfSWxzQVNPWXIxM1pObHAzWGRuNnlIUF9vRnJMd0hqYWc?oc=5","date":"2025-09-17","type":"pipeline","source":"BioPharma Dive","summary":"Ollin debuts with $100M and plans to challenge top-selling eye drugs - BioPharma Dive","headline":"Ollin debuts with $100M and plans to challenge top-selling eye drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOVHFhZFBocjdyb05DMjF4Zl9zYlpyYjFkUHpmOXdHcFB3N1o0TG8ydl9hclI2NTlHUV84Sk8xOUZ6RzNqLUF2aEZieVFkRFZnNS1ObWxJMHExX2kySkxtRTZfam0yd2lpWEk0SXgyTXNYZWE1dk51NVdpeVB3RzFoTDdESkxYZW9JQ0drYTFoWWFYUjRESm5oQ2RsQXBOSkg4V1Q5YWxqMDdHN1MzWjFGRjZyd2t4NmU2UnotLUZ0MEdHVVk0Y1QzVVBydUhEQlFrQmJtWFJOSnVDVjVYRjlkLTV1Mzkydw?oc=5","date":"2025-09-17","type":"pipeline","source":"Business Wire","summary":"Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology - Business Wire","headline":"Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNYjlMRW1KTmhTdFMwMk5SU3RfUjV1eXpoT1ZScVFyb1ZSNl9keU5PekdZNERzWGRhVVBDNk9mNFFHT3A5RHVYY0JNVUxxT3V4Z3ExOUJHM2hkcTJVdlMtQ1IwQTlBaDJjMHZOTUlmM0plQ3NHSHZYbHhRY0ZfM2VfTzRyeWpsOVNGZkUwMlg5NmM?oc=5","date":"2025-09-17","type":"pipeline","source":"Ophthalmology Times","summary":"Ollin Biosciences announces its official launch - Ophthalmology Times","headline":"Ollin Biosciences announces its official launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQc0ptTHNfSjNQS1U3M195bjlFcXloUWtOMG5hWGJRemx5LTJucXFCS1paa0dEV3Voak81Ym44WDlvcVhiMDh3LUx6QzBxeXlTakhCLUpCV01QazVHYmNYdEd2T1FJT2lZUDlCU01ldTV2aGtRZ1hzZjlsNTZralMyQ2VaNTJ3NFlzVjZCTUtDNEN5QzMyWGlYcVhaZzJ4OFg3?oc=5","date":"2025-09-17","type":"pipeline","source":"BioWorld News","summary":"Ollin eyes next-gen ophthalmology space, launches with $100M - BioWorld News","headline":"Ollin eyes next-gen ophthalmology space, launches with $100M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5CaExyQUtmelgtYzhnSzluRF9DYUlYSnJxUEtNTXMtYnNtRHBCY0xIUEI4NVVjM0JpaHczUDlFNHhMTDRPUzB4RnBlSkEyN2tzX0wzSl9TMDNzVXFiNWc?oc=5","date":"2025-04-21","type":"pipeline","source":"The Pharma Letter","summary":"Ollin Biosciences - The Pharma Letter","headline":"Ollin Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPZFBIVjlqRFJYekVoYWpNZ3VDQmhfSy1sYTlibk5sY0U2bHJiRXRzNUoyMkdiNDRPM01yWHFrY1p1dU1mcW5qQlVqX05iaGRZanFkbkJmbXRfeHRKRWpKZnltUktYZnVWT2NneHUtcVNVaW5PTXNyU0tjT1RTaEo1UmdlV25ZSndXN1R5MDhxMTVzS2xJMEstcFJYNWhiYTRyQ0xJaDFzTnFveXFQLXVzNWJHQjJMa05Mbmlvb0tkSjFGWldDWGRoajZHLUxtZnN1NjBlb09qTXhkS3NPdGhaeGZHMkJzZ3Nrbml5WnVOakI?oc=5","date":"2025-04-18","type":"deal","source":"BioPharma APAC","summary":"VelaVigo Bio Signs $440M Global Licensing Deal with Ollin Biosciences for First-in-Class Bispecific Antibody VBS-102 - BioPharma APAC","headline":"VelaVigo Bio Signs $440M Global Licensing Deal with Ollin Biosciences for First-in-Class Bispecific Antibody VBS-102","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPYi1MRU9ES1RRMjhsN2JmQlJXWUhQZmVnd0NUSmVEMUdlMEF1UFB6VEhnaFI1SXJycnRZVG9YY1dVMGRMeUJ5SUowdk1JZXlfN2VaWmdsRmgzRVRGQUQxVFlzTVdUaWFfd0ZSWTZ4V3lrR0hCbm1LdVV2YXJaQzVKR3AwU2Q5VERRTk9HQjE1UUh3cjltQTNvOUVfOA?oc=5","date":"2025-04-18","type":"deal","source":"Fierce Biotech","summary":"Stealth biotech bags rights to VelaVigo bispecific in $440M deal - Fierce Biotech","headline":"Stealth biotech bags rights to VelaVigo bispecific in $440M deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}